Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Rift Valley fever MP-12 vaccine Phase 2 clinical trial: Safety, immunogenicity, and genetic characterization of virus isolates.

Pittman PR, Norris SL, Brown ES, Ranadive MV, Schibly BA, Bettinger GE, Lokugamage N, Korman L, Morrill JC, Peters CJ.

Vaccine. 2016 Jan 20;34(4):523-530. doi: 10.1016/j.vaccine.2015.11.078. Epub 2015 Dec 17.

2.

Managing potential laboratory exposure to ebola virus by using a patient biocontainment care unit.

Kortepeter MG, Martin JW, Rusnak JM, Cieslak TJ, Warfield KL, Anderson EL, Ranadive MV.

Emerg Infect Dis. 2008 Jun;14(6):881-7. doi: 10.3201/eid1406.071489.

3.

Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis.

Pittman PR, Leitman SF, Oro JG, Norris SL, Marano NM, Ranadive MV, Sink BS, McKee KT Jr.

Clin Diagn Lab Immunol. 2005 Jun;12(6):713-21.

4.

Biological effects of trinitrotoluene from exposure below the threshold limit value.

Morton AR, Ranadive MV, Hathaway JA.

Am Ind Hyg Assoc J. 1976 Jan;37(1):56-60.

PMID:
1246950
5.

Pulmonary function in shipyard welders: an epidemiologic study.

Peters JM, Murphy RL, Ferris BG, Burgess WA, Ranadive MV, Perdergrass HP.

Arch Environ Health. 1973 Jan;26(1):28-31. No abstract available.

PMID:
4682846

Supplemental Content

Loading ...
Support Center